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Aggressive variant prostate cancers (AVPC) are a clinically defined
group of tumors of heterogeneous morphologies, characterized by
poor patient survival and for which limited diagnostic and treat-
ment options are currently available. We show that the cell surface
78-kDa glucose-regulated protein (GRP78), a receptor that binds to
phage-display-selected ligands, such as the SNTRVAP motif, is a
candidate target in AVPC. We report the presence and accessibility
of this receptor in clinical specimens from index patients. We also
demonstrate that human AVPC cells displaying GRP78 on their
surface could be effectively targeted both in vitro and in vivo by
SNTRVAP, which also enabled specific delivery of siRNA species to
tumor xenografts in mice. Finally, we evaluated ligand-directed
strategies based on SNTRVAP-displaying adeno-associated virus/
phage (AAVP) particles in mice bearing MDA-PCa-118b, a patient-
derived xenograft (PDX) of castration-resistant prostate cancer bone
metastasis that we exploited as a model of AVPC. For theranostic (a
merging of the terms therapeutic and diagnostic) studies, GRP78-
targeting AAVP particles served to deliver the human Herpes sim-
plex virus thymidine kinase type-1 (HSVtk) gene, which has a dual
function as a molecular-genetic sensor/reporter and a cell suicide-
inducing transgene. We observed specific and simultaneous PET im-
aging and treatment of tumors in this preclinical model of AVPC.
Our findings demonstrate the feasibility of GPR78-targeting, ligand-
directed theranostics for translational applications in AVPC.
aggressive variant prostate cancer | ligand-directed theranostics | molecular
imaging | gene therapy | AAVP
Prostate cancer, the most common carcinoma in men and amajor cause of morbidity and mortality (1), is a clinically het-
erogenous disease. Although a majority of prostate cancers are
highly responsive to androgen receptor (AR)-directed therapies, a
subset is relatively resistant to these therapies and carries a dismal
prognosis (2–5). At the extreme of this spectrum are the small-cell
or neuroendocrine carcinomas, a predominantly AR-negative his-
tological variant of the disease that is associated with atypical
clinical features (such as visceral metastases, predominantly lytic
bone metastases, low levels of prostate-specific antigen relative to
tumor burden, bulky primary tumors, and high levels of lactic
dehydrongenase and carcinoembryonic antigen) and responds to
platinum-based chemotherapies (6). Although small-cell or neu-
orendocrine carcinomas of the prostate are rare at initial diagnosis,
they are increasingly recognized in the castration-resistant phases
of disease progression. Moreover, a larger group of morphologi-
cally heterogeneous prostate cancers share the clinical features
of the small-cell neuroendocrine carcinomas and, likely, their un-
derlying biology (7, 8); these have been grouped under the term
aggressive variant prostate carcinomas (AVPC). The molecular
underpinnings of the AVPC are likely shared with subsets of other
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of untreatable and hard to diagnose aggressive tumor variants.
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epithelial tumors, such as the triple-negative breast cancers. How-
ever, molecular-imaging tools and specific therapeutic approaches
tailored to the AVPC are lacking.
To evaluate potential “theranostic” (a merging of the terms
therapeutic and diagnostic) strategies for AVPC, we exploited
SNTRVAP, a peptide motif isolated by screening of combinatorial
phage display libraries in the MDA-PCa-118b patient tumor-derived
xenograft (PDX) in vivo (9, 10) (Fig. 1). SNTRVAP is a ligand to a
functional supramolecular complex present on the cell surface and
containing the 78-kDa glucose-regulated protein (GRP78), an en-
doplasmic reticulum chaperone involved in prosurvival mechanisms
(11). Altered glucose metabolism of cancer cells, as well as glucose
starvation in poorly vascularized tumors, are associated with GRP78
overexpression and translocation to the cell surface (12–14). Over-
expression of GRP78 has been correlated with poor survival in
patients with breast (15–17) and prostate cancer (10, 18–20). Its
tumor-specific localization and stress-response attributes make cell
surface GRP78 an attractive candidate receptor for ligand-directed
strategies in solid tumor management (10, 21). Chimeric adeno-
associated virus/phage (AAVP) particles (22–25) combine eukary-
otic virus transduction efficiency to phage-targeting attributes. In
this hybrid construct, the targeting agent (a ligand peptide) is
expressed as a fusion within the phage pIII capsid protein, whereas
the effector agent (a transgene) is inserted into the phage genome as
a fully functional expression cassette under the control of a consti-
tutive CMV promoter. Ligand-directed AAVP particles have been
successfully evaluated in several preclinical transgenic and xenograft
tumor-bearing mouse models, including carcinomas of the breast
and prostate (22), soft-tissue sarcomas (26), and glioblastomas (27).
Moreover, AAVP-mediated tumor vascular delivery of TNF has
proven efficacy in human melanoma xenografts (28) and pancreatic
neuroendocrine transgenic tumors (29), as well as in native tumors
in dogs (30). Here we investigated the GRP78-targeting properties
of SNTRVAP (10), exploiting its specific binding to cell surface
GRP78 for tumor targeting in the MDA-PCa-118b PDX.
SNTRVAP-directed, GRP78-targeting AAVP particles were used
to deliver the human Herpes Simplex virus thymidine kinase type-1
(HSVtk) gene to act as both a noninvasive molecular-genetic im-
aging sensor/reporter, in the presence of a radiolabeled substrate,
and a cell suicide-inducing transgene in the presence of ganciclovir
(GCV), which is converted to a cytotoxic by HSVtk-expressing
cells. This strategy proved to be effective as a targeted theranostic
in preclinical models. GRP78-targeting AAVP particles are essen-
tially “clinic-ready” for translation into urologic oncology.
Results
The Ligand Peptide SNTRVAP Targets Cell Surface GRP78 in AVPC.We
first investigated the amount and localization of GRP78 in a pilot
cohort of de-identified patients with primary small cell prostate
carcinoma (n = 4). This initial analysis revealed a range from
moderate-to-strong GRP78 immunostaining in both cytoplasm
and cell surface in all patient-derived tumor samples examined
(Fig. 2), a promising result in the light of translational applications.
We next mapped the SNTRVAP:GRP78 interaction interface
with an alanine-scanning site-directed mutagenesis approach (31).
Phage particles displaying the parental SNTRVAP motif were
compared with mutant particles in which each residue was indi-
vidually converted to an alanine (or to glycine in the case of alanine
itself in the parental motif) for binding to recombinant GRP78
in vitro. These assays showed that none of the residues were
dispensable for the interaction: decreased binding to GRP78,
ranging from partial (50–75%; site-directed mutagenesis of Ser1,
Thr3, Arg4, or Ala6) to complete (>75%; site-directed muta-
genesis of Asn2, Val5, or Pro7) inhibition was observed for all mu-
tants compared with the parental motif (Fig. 3A). These results
are consistent with the concept that a three-residue motif in the
primary structure is necessary and sufficient for peptide-protein
recognition (32). SNTRVAP specificity was further validated in
DU145, a human prostate cancer-derived cell line developed
from a brain metastases—which is AR-negative—Tp53 and p16
mutant, and results in lytic bone metastases when implanted in
mice, all features that overlap with clinical and molecular fea-
tures of AVPC (7, 8). Importantly, these cells express high levels
of GRP78, and are therefore a suitable model for ligand-directed
approaches. To obtain an internal control for specificity, GRP78
was silenced by small-hairpin RNA (shRNA). We observed that
two of five GRP78 shRNA vectors (i.e., clones #3 and #5) effec-
tively down-modulated GRP78 (Fig. 3B), and consequently led to a
Fig. 1. Schematic representation of the MDA-PCa-118b PDX model gener-
ation and applications. (A) Index patient CT scan illustrating the original
bone metastasis from which the MDA-PCa-118b PDX was obtained and
propagated by subcutaneous injection in immunodeficient mice. (B) Sequen-
tial examples of translational research with this PDXmodel toward the present
characterization of a ligand-directed theranostic approach for AVPC.
Fig. 2. GRP78 protein is expressed both in the cytoplasm and at the cell
surface in AVPC specimens from patients. (A) Pathological evaluation of a
representative specimen with high-grade cytology, small cell features, nuclear
molding, and necrosis (H&E). (B) The same tumor stained for GRP78, moderate-
to-strong (2–3+) intensity in tumor cells. (C) GRP78 staining of a representative
case showing weak (1+) but diffuse positivity. (D) GRP78 staining of a repre-
sentative case showing strong (3+) intensity. (Inset) Staining of normal pros-
tate gland. (Magnification: A–D, 40×; Inset, 5×.)
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commensurate decrease in cell surface binding of GRP78 to
SNTRVAP-displaying phage particles (Fig. 3C) (P < 0.05 by two-
tailed Student’s t test). Taken together, these results confirm a specific
interaction between the SNTRVAP and GRP78, and support
the possibility of exploiting this ligand-receptor in AVPC.
SNTRVAP Targets GRP78-Expressing Tumor Xenograft Models in Vivo.
We next validated the targeting efficacy of SNTRVAP in immu-
nodeficient mice implanted with either parental or GRP78-
silenced DU145 tumor cells. Differential GRP78 expression levels
in tumor xenografts were confirmed by immunohistochemistry
(IHC) (Fig. 4A) and quantification of specific signals (Fig. 4B).
GRP78-targeting or control phage particles were administered
intravenously into DU145-derived tumor-bearing mice, and phage
particle localization was evaluated after 24 h by staining with an
antiphage antibody (33) (Fig. 4C), followed by quantification of
DAB signals (Fig. 4D) and titration of phage particles by quanti-
tative PCR (qPCR) (34) (Fig. 4E). The GRP78-targeting phage
particles localized in parental DU145-derived tumors but not in
size-matched GRP78-silenced DU145-derived tumors. Regardless
of cell surface GRP78 levels, control phage particles did not ac-
cumulate in tumor xenografts. GRP78-targeting or control phage
particles were present in the liver because of the long-recognized
virus retention by the reticuloendothelial system (35–37), whereas
neither was detectable in control tissues. Taken together, these
results establish that the ligand peptide SNTRVAP targets AVPC-
like cells that express cell surface GRP78 in vivo.
Targeting Cell Surface GRP78-Expressing Cells for in Vitro and in Vivo
Small-Interfering RNA Delivery. As another step toward potential
applications of the GRP78-targeting peptide motif, we explored
the possibility of delivering small-interfering RNA (siRNA) and
shRNA species to tumors that express cell surface GRP78.
Transduction of parental GRP78-expressing DU145 cells was first
evaluated in vitro with a custom GAPDH-specific siRNA conju-
gated to the GRP78-targeting peptide SNTRVAP, in comparison
with GAPDH-specific siRNA administered by a standard trans-
fection system (NeoFX). Quantification of GAPDH mRNA
showed that the GRP78-targeting system is twice as effective as
the standard reference. Equimolar concentrations of either an
unconjugated GAPDH siRNA or a GRP78-targeting control
siRNA were ineffective, further supporting the ligand-receptor
specificity (Fig. 5A). We next coupled the GRP78-targeting
peptide to a GRP78 siRNA sequence (Fig. 5B). The efficacy of
this GRP78-targeting GRP78 siRNA was evaluated in vivo in
comparison with a control unconjugated siRNA. Forty-eight hours
after siRNA administration into DU145 tumor-bearing mice, ei-
ther GRP78-targeting or control phage particles were adminis-
tered intravenously and allowed to circulate for 24 h, followed by
tumor collection. Quantification of tumor-retrieved phage parti-
cles revealed an inhibition (>40%) of GRP78-targeting particles
Fig. 3. In vitro validation of SNTRVAP and GRP78 as a ligand-receptor.
(A) Ala-scanning site-directed mutagenesis of SNTRVAP. Each residue in the
SNTRVAP sequence was mutated and the resulting phage particles were tested
for binding to recombinant GRP78. Results are shown after normalization as
the mean ± SEM in triplicate wells. (B) In vitro GRP78 silencing. DU145 cells
were infected with lentiviral vectors expressing different GRP78 shRNA con-
structs, and GRP78 levels were assessed by Western blot. β-Actin served as a
loading control. (C) The GRP78-targeting phage specifically binds to DU145
cells expressing cell surface GRP78. Binding is shown as transducing units (TU)
relative to the control phage, *P < 0.05 by two-tailed Student’s t test.
Fig. 4. In vivo validation of SNTRVAP and GRP78 as a ligand-receptor.
(A) Animal models of GRP78-expressing and -silenced AVPC. DU145 cells
transduced with control or GRP78 shRNA were injected subcutaneous into
the flank of athymic BALB/c mice and tumors were grown for 6–8 wk. H&E
staining (Upper) and GRP78 IHC (Lower) are shown. (B) Quantification of
GRP78 staining was obtained by deconvolution with ImageJ and is expressed
as number of pixels per optical field. (C) In vivo accumulation of GRP78-
targeting phage. Phage localization was evaluated on excised tumor masses
by IHC. Liver and muscle were used as control organs. (D) Quantification of
IHC signals was obtained as in B. (E) Phage DNA was extracted and quan-
tified by qPCR. Numbers of phage particles per 100 ng of total DNA are
represented as mean ± SEM. Magnification in A and C is 20×.











in tumor-bearing mice pretreated with GRP78-targeting GRP78-
siRNA, compared with the control siRNA. Finally, the corre-
sponding control particles were not detected in tumors of treated
mice (Fig. 5C). These results demonstrate that the SNTRVAP
can target a GRP78-specific siRNA and effectively down-mod-
ulate GRP78 on AVPC cells in vivo.
SNTRVAP Mediates GRP78 Targeting for Transgene Delivery to a PDX
Model. Having confirmed the efficacy and specificity of GRP78
targeting via the ligand peptide SNTRVAP in vitro and in vivo, we
evaluated the efficacy of GRP78-targeting AAVP particles for
in vivo genetic transduction of GRP78-expressing tumors (22). As
mentioned above, the HSVtk gene product (thymidine kinase)
functions as (i) an imaging tool in the presence of a radiolabeled
substrate, and (ii) a cell suicide-inducing transgene in the presence
of GCV (38). We evaluated both functions toward theranostic
anti-AVPC strategies. Mice bearing the MDA-PCa-118b PDX
model were randomized into four cohorts receiving: (cohort 1)
control AAVP plus saline; (cohort 2) GRP78-targeting AAVP
plus saline; (cohort 3) control AAVP plus GCV; (cohort 4)
GRP78-targeting AAVP plus GCV. Daily treatments with either
saline or GCV were started 5 d after intravenous administration of
AAVP particles, as indicated, and continued for 7 d. Twenty-four
hours after the last treatment, mice received [18F]-fluorodeox-
yglucose ([18F]-FDG) to assess tumor viability as a function of
glucose metabolism by PET/CT. Expression of the HSVtk trans-
gene was evaluated after another 24 h by PET immediately after
intravenous administration of 2-[18F]-fluoro-2-deoxy-1-D-arabino-
furanosyl-5-ethyluracil ([18F]-FEAU) (26, 39). (See Supplemental
Discussion: Comparison Between the [18F]-FEAU and 124I-FIAU
Substrates for more on the [18F]-FEAU substrate). Cohorts 1 and 2
were evaluated in protocols for ligand-directed molecular-genetic
imaging. In these PDX-bearing mice, GRP78-targeting AAVP
particles specifically localized at sites superimposable with meta-
bolically active tumors, as visualized by [18F]-FDG PET/CT scans,
whereas the control AAVP particles did not show specific accu-
mulation (Fig. 6A). Nonspecific localization of both [18F]-FDG and
[18F]-FEAU in the kidneys and urinary bladder was observed in all
cohorts as a result of renal clearance. Quantification of [18F]-
FEAU (represented here as percentage of the [18F]-FEAU dose
administered) confirmed that HSVtk tumor expression in mice re-
ceiving GRP78-targeting AAVP particles was significantly higher
than in mice receiving control AAVP particles (P < 0.001 by two-
tailed Student’s t test) (Fig. 6B). PDX-bearing mouse cohorts 3 and
4 were evaluated in protocols for ligand-directed therapy. PET/CT
scans demonstrated decreased tumor size in GRP78-targeting
AAVP-administered mice treated with GCV, compared with the
control AAVP plus GCV (Fig. 6C). This inhibition of tumor growth
in PDX-bearing mice treated with GRP78-targeting AAVP plus
GCV was independently confirmed by measuring gross tumor sizes
with calipers, which revealed an average 50% reduction in tumor
size (P < 0.001 by two-tailed Student’s t test) (Fig. 6D). Excised
tumors were also subjected to microtomography to quantify the
percentage of mineralized tissue, a typical feature of osteoblastic
metastases from prostate cancer. The growth of densely mineral-
ized bone was significantly suppressed in animals treated with
GRP78-targeting AAVP plus GCV, compared with treatments
with GRP78-targeting AAVP plus saline or control AAVP (P <
0.05 by 2-way ANOVA followed by Bonferroni’s test) (Fig. 7A).
PDX tumors from mice treated with GRP78-targeting AAVP plus
GCV were highly apoptotic as visualized by TUNEL staining, as
opposed to tumors in mice treated with either GRP78-targeting
AAVP plus GCV or control AAVP (Fig. 7B). These data were
confirmed by the quantification of specific IHC signals (Fig. 7C).
These results demonstrate the efficacy of the peptide SNTRVAP
for ligand-directed strategies that target GRP78 as a cell surface
receptor in a clinically-relevant model of AVPC.
Discussion
The combination of improved management and longevity of
prostate cancer patients, along with increasing awareness of
AVPC (7, 8), has led to a need for more specific tools for detec-
tion and treatment of this aggressive phenotype. Given that patients
with AVPC are relatively insensitive to AR-directed therapies, and
respond only transiently to chemotherapy (2–8), the development
of a strategy that would work across molecular and cellular diversity
in AVPC remains an unmet need. New technological approaches,
such as the emerging field of theranostics, may prove useful to
enable biopsy-free spatiotemporal tumor monitoring. As a proof-
of-concept for serial ligand-directed theranostics, we herein provide
preclinical applications of simultaneous noninvasive molecular-
genetic imaging and therapy of AVPC based on targeting the
tumor cell surface receptor GRP78.
Fig. 5. In vitro and in vivo ligand-directed silencing of GRP78. (A) The GRP78-targeting peptide, chemically conjugated to a GAPDH siRNA, was incubated
with GRP78-expressing DU145 cells followed by evaluation of GAPDH mRNA levels. GAPDH siRNA transfection with NeoFX was used as a standard. An
unrelated siRNA and an unconjugated GRP78-targeting peptide were used as controls. Values are expressed as percent silencing of GAPDH. (B) Conjugation
scheme of GRP78-targeting peptide to the 5′-modified GRP78 sense-strand siRNA. (C) GRP78-targeting siRNA or control siRNA were injected intravenously
into DU145 tumor-bearing mice 48 h before intravenous injection of either untargeted or GRP78-targeting phage. After 24 h, tumors were excised and phage
was quantified by bacterial infection. Values are expressed as percent accumulation compared with GRP78-targeting phage on nonsilenced cells, and are
shown as mean ± SEM of three experiments.
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The MDA-PCa-118b PDX used in this work was unique in
being a fully characterized in vivo model of osteogenic prostate
cancer (9), and it has subsequently been used to unveil molecular
mechanisms in metastatic tumors of the prostate (10, 40–42). The
MDA-PCa-118b PDX is both castration-resistant and capable of
developing soft-tissue and osteogenic tumors in mice (9), indicat-
ing that it is indeed representative of the highly aggressive pa-
thology spectrum of AVPC; therefore, one may assume that the
inherent mechanisms of disease progression, experimental findings,
and targeting concepts uncovered by using the MDA-PCa-118b
PDX are generalizable to the large “universe” of AVPC patients.
By in vivo selection of phage-display random peptide libraries in
the MDA-PCa-118b PDX, we have recently identified SNTRVAP
as a highly specific ligand to GRP78 on the surface of cells within
and adjacent to bone-like tumors (10). GRP78 up-regulation and
relocation to tumor cell surface are associated with aggressive
growth and invasive properties, and have been previously reported
in human cancer cell lines and tissues (12). In prostate cancer,
GRP78 expression levels correlate with the development of a
metastatic disease in which circulating anti-GRP78 auto-antibodies
are indicative of poor survival (21, 43). These observations support
a potential translation of GRP78-based theranostics for the man-
agement of AVPC, including the widespread metastatic burden
that remains a major clinical feature of AVPC patients (7, 8, 44).
Additional GRP78-binding sequences, such as Trp-rich peptide
motifs, have been reported (21, 45). Among these peptides,
WIFPWIQL targets cell surface GRP78 in tumor-bearing mice and
in human specimens of prostate cancer (10, 21, 22). Similar ap-
plications of this peptide are reported in our companion article on
aggressive variants of breast cancer (46). Here, we chose the
peptide SNTRVAP (10) to target AVPC for several reasons: (i) its
original selection in the MDA-PCa-118b PDX itself; (ii) its selec-
tivity for a prostate cancer-specific cell surface supramolecular
complex that incorporates GRP78, prostate-specific antigen, and
α2 microglobulin (10, 47); (iii) its ability to bind AVPC cells either
per se or loop-grafted into an antibody backbone; and (iv) its su-
perior hydrosolubility relative to the GRP78-binding Trp-rich
motifs, which generally harbingers cost-effective production
yields in aqueous formulations.
Our studies validate the application of GRP78-targeting AAVP
particles as molecular-genetic imaging tools for PET/CT applica-
tions, in agreement with the increased expression of cell surface
GRP78 during metastatic progression and, in general, in the most
aggressive castration-resistant forms of prostate cancer collectively
included in the broad definition of AVPC (7, 8). Besides staging
and active surveillance of prostate cancer during treatment, such a
biomarker-annotated theranostic strategy is expected to provide
specific ligand-directed detection of biochemical relapse: that is, to
reveal the earliest possible recurrence of GRP78+ tumor cells.
Fig. 6. Ligand-directed theranostics of the MDA-PCa-118 PDX model.
(A) PET/CT imaging of MDA-PCa-118b PDX-bearing mice administered in-
travenously with GRP78-targeting or control AAVP. The pseudocolor scale
represents signal intensity of [18F]-FDG (metabolic activity) or [18F]-FEAU
(HSVtk activity). ***P < 0.001 by two-tailed Student’s t test. (B) Quantifica-
tion of HSVtk gene expression by micro-PET imaging of [18F]-FEAU substrate.
***P < 0.001 by two-tailed Student’s t test. (C) PET/CT imaging of MDA-PCa-
118b PDX-bearing mice administered as in A, and 7 d later treated with
GCV for 5 d. (D) Tumor sizes were assessed by caliper measurement. ***P <
0.01 by two-way ANOVA followed by Bonferroni’s test.
Fig. 7. GRP78-targeting AAVP particles reduce bone density and induce apoptosis in GCV-treated MDA-PCa-118b PDX models. (A) Evaluation of bone density
of implanted tumors. (B) H&E staining and TUNEL assays were performed on MDA-PCa-118b tumor sections from mice administered intravenously with
control or GRP78-targeting AAVP particles, and treated with saline or GCV. Control, secondary antibody only. (Magnification: 20×.) (C) DAB signals were
isolated by deconvolution and quantified with ImageJ, and are represented as number of pixels per optical field. *P < 0.05 by two-way ANOVA followed by
Bonferroni’s test.











Remarkably, this theranostic tool enables simultaneous therapeutic
options that address the composite disease burden in valuable
models of human AVPC. In summary, GRP78-targeting AAVP
particles provide an efficient approach to address preclinical
models of human AVPC for imaging and therapy and, as such,
should be considered for translation into clinical applications in
patients with this aggressive disease phenotype. Given that AVPC
patients share complex genetic and epigenetic lesions (48), AAVP-
based transcriptomic reporter analysis of promoter-mediated gene
expression may be incorporated into the ligand-directed theranostic
approach introduced here.
Materials and Methods
Theuse of human sampleshasbeen reviewedandapproved by theClinical Ethics
Service, Institutional Biohazard Committee, Clinical Research Committee, and
Institutional Review Board of the University of New Mexico Comprehensive
Cancer Center. The animal experiments were reviewed and approved by the
Institutional Animal Care and Utilization Committee of M. D. Anderson Cancer
Center. Reagents andall experimentalprocedures, such as the designof targeted
AAVP and all in vivo and in vitro applications, are fully described in SI Materials
and Methods.
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SI Materials and Methods
Cell Lines, Reagents, and Human Specimens.The PDX model MDA-
PCa-118b (9) was obtained from the Prostate Cancer Patient-
derived Xenograft Program at the University of Texas M. D.
Anderson Cancer Center (MDACC). Human prostate cancer-
derived cell lines were purchased from the American Type Culture
Collection (ATCC) and cultured in Cellgro (Mediatech), supple-
mented with 10% (vol/vol) heat-inactivated FBS (Invitrogen Life
Technologies), penicillin, and streptomycin (all from Gibco), in a
5% CO2 cell culture incubator at 37 °C. All cell line identities were
verified by short tandem-repeat microsatellite loci analysis. Frozen
stocks were generated at the time of authentication and were thawed
for experiments no more than 3 mo before use. All tumor cell lines
used in tissue culture were tested and documented to be free from
contamination by Mycoplasma. The GRP78-targeting soluble
peptide SNTRVAP (10), along with the corresponding controls,
was custom-manufactured (PolyPeptide Laboratories) and qual-
ity-controlled to our specifications [>95% (wt/wt) purity]. Human
recombinant GRP78 (Stressgen Bioreagents) and the SNTRVAP-
GAPDH siRNA (Sigma-Aldrich) were obtained commercially.
De-identified archival AVPC specimens were obtained from
patients with small cell prostate carcinoma treated at the Uni-
versity of New Mexico Comprehensive Cancer Center. This study
adheres to current medical ethics recommendations and guidelines
on human research, and has been reviewed and approved by the
Clinical Ethics Service, Institutional Biohazard Committee, Clinical
Research Committee, and Institutional Review Board of the Uni-
versity of New Mexico Comprehensive Cancer Center.
Immunohistochemistry. Formalin-fixed paraffin-embedded (FFPE)
samples from the Human Tissue Repository Core at the University
of New Mexico Comprehensive Cancer Center were stained in a
Ventana Discovery XT biomarker platform with standardized
apparatus, reagents, and protocols provided by the manufac-
turer (Ventana Medical Systems). Primary anti-GRP78 rabbit
monoclonal antibody (Cell Signaling Technology) was used
at 1:200. Following incubation in HRP-conjugated anti-goat
secondary antibody (Santa Cruz Biotechnology), signal was
detected with DAB chromogenic substrate (Dako). Staining of
patient samples was evaluated with standard pathology pro-
tocols, applying a four-value intensity score (0, none; 1+, weak;
2+, moderate; 3+, strong). Quantification of IHC signals in
mouse tissues was obtained by color deconvolution followed
by DAB+ pixel counts with the Fiji image processing package
of ImageJ (49).
Site-Directed Mutagenesis of GRP78-Targeting Phage Particles. Mu-
tant phage particles displaying alanine-scanning variants of
SNTRVAP were prepared by site-directed PCR mutagenesis as
described (34). Briefly, the following oligonucleotide pair sets
(Sigma-Genosys) were annealed in 10 mM Tris·HCl pH 8.0,
containing 100 mMNaCl, 1 mMEDTA at 10 nM, and cloned into






CCGTGTGGGGCCGCTG, and CANTRVAPC-r: CGGCCCC-
ACACGGCGCCACGCGGGTGTTCGCACAAGCCCCGT;
CSATRVAPC-f: GGGCTTGTAGCGCGACCCGCGTGGC-
GCCGTGTGGGGCCGCTG, and CSATRVAPC-r: CGGCCC-
CACACGGCGCCACGCGGGTCGCGCTACAAGCCCCGT;
CSNARVAPC-f: GGGCTTGTAGCAACGCGCGCGTGGCG-
CCGTGTGGGGCCGCTG, and CSNARVAPC-r: CGGCCCC-
ACACGGCGCCACGCGCGCGTTGCTACAAGCCCCGT;
CSNTAVAPC-f: GGGCTTGTAGCAACACCGCGGTGGC-
GCCGTGTGGGGCCGCTG, and CSNTAVAPC-r: CGGCCC-
CACACGGCGCCACCGCGGTGTTGCTACAAGCCCCGT;
CSNTRAAPC-f: GGGCTTGTAGCAACACCCGCGCGGCGC-
CGTGTGGGGCCGCTG, and CSNTRAAPC-r: CGGCCCC-
ACACGGCGCCGCGCGGGTGTTGCTACAAGCCCCGT;
CSNTRVGPC-f: GGGCTTGTAGCAACACCCGCGTGGG-
CCCGTGTGGGGCCGCTG, and CSNTRVGPC-r: CGGCCC-
CACACGGGCCCACGCGGGTGTTGCTACAAGCCCCGT;
CSNTRVAAC-f: GGGCTTGTAGCAACACCCGCGTGGC-
GGCGTGTGGGGCCGCTG, and CSNTRVAAC-r: CGGCCC-
CACACGCCGCCACGCGGGTGTTGCTACAAGCCCCGT.
RP78 Silencing by shRNA.Five alternativeMission shRNA sequences
(Sigma-Aldrich) targeting the human GRP78 were cloned into the
retroviral vector pLKO.1, and are referred to as GRP78-shRNA
clones 1–5. A control vector was obtained by insertion of the se-
quence 5′-UUCUCCGAACGUGUCACGU-3′. Lentiviruses were
produced by cotransfecting 293FT cells (Invitrogen) with each of
the deriving pLKO.1 vectors combined with a packaging plasmid
(MD2G) and an envelope-coding plasmid (PAX2). After 72 h,
viral supernatants were collected and filtered to remove cellular
debris. To silence GRP78, human prostate cancer cells were
plated at 70% confluence in six-well plates and transduced with
the individual GRP78-shRNA or control lentivirus, and GRP78
expression was evaluated after 48 h. To obtain stably-silenced cells,
16 h after transduction with the indicated GRP78-shRNA species,
medium was replaced and transduced cells were selected in pu-
romycin (2 μg/mL).
Design and Construction of Bifunctional (GRP78-Targeting, GRP78-
Silencing) siRNA. The SNTRVAP-GRP78 siRNA conjugate was
obtained by 5′-end coupling of the 3′-protected sense strand of
GRP78 siRNA sequence #5 (Dharmacon) with the soluble
SNTRVAP peptide through a phosphoramidate bond. The re-
sulting conjugate was purified and desalted, followed by de-
protection of both strands, annealing, and precipitation according
to standard protocols. A GAPDH siRNA (Mission, Sigma-Aldrich,
ID: SASI_Hs01_00140981) served as a control.
Phage Binding Assays. For protein-phage binding assays, recombi-
nant GRP78 or BSAwas immobilized onmicrotiter wells overnight
at 4 °C (1 μg per well). Wells were blocked in PBS containing
3% (wt/vol) BSA for 2 h at room temperature, and incubated for
1 h at room temperature with 1 × 109 TU of each phage. For cell-
phage binding assays with the BRASIL method (50), 1 × 106
human prostate cancer cells were incubated with 1 × 109 TU of
each phage for 2 h on ice and successively collected by centrifu-
gation. Bound phage particles were recovered by bacterial in-
fection, purified and quantitated as described previously (51).
Western Blot. Proteins were resolved on SDS/PAGE precast gels
(Bio-Rad), transferred to nitrocellulose membranes (Bio-Rad),
incubated with primary anti-GRP78 (Cell Signaling Technology)
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or anti–β-actin (Sigma) antibody, washed and incubated with
HRP-conjugated secondary antibodies. Immunoreactive bands
were visualized by enhanced chemiluminescence (ECL, Bio-Rad).
Animal Models. Six- to 8-wk-old male immunodeficient BALB/c
athymic or CB17 SCIDmice (Charles River Laboratory) were kept
on a 12-h-light/dark cycle.Rodent chow andwater were available ad
libitum. DU145 xenografts were established in BALB/c athymic
mice by subcutaneous injection of 1 × 106 cells. The MDA-PCa-
118b PDX was propagated and maintained by subcutaneous pas-
sages in CB17 SCID mice as previously described (9). During all
imaging and surgical procedures, animals were anesthetized [either
isoflurane 2% (vol/vol) in oxygen or tribromoethanol, 250 mg/kg],
and their temperature was maintained at 38 °C with a heat-lamp.
The animal experiments reported in this paper were performed at
the M. D. Anderson Cancer Center. All experimentations were
conducted in full compliance with the corresponding Institutional
Animal Care and Utilization Committee policies and procedures,
which follows a strict current guide care and use of laboratory
animals (52). Before the initiation of any animal experiments, all
protocols and procedures were reviewed and approved by the local
Institutional Animal Care and Utilization Committee of the orga-
nization in which the experiments were executed.
GRP78-Targeting Phage Homing in Vivo. Specific homing of GRP78-
targeting phage particles was evaluated: (i) in mice implanted with
cell surface GRP78-expressing human prostate cancer cells (in
comparison with mice implanted with GRP78-silenced cells), and
(ii) in mice implanted with cell surface GRP78-expressing human
prostate cancer cells and administered intravenously (5 nmol per
mouse) with control siRNA (in comparison with mice adminis-
tered with the same molar dose of the SNTRVAP-GRP78 siRNA
conjugate). In both experimental settings, tumor-bearing mice
received an intravenous administration of 2 × 1010 TU of either
SNTRVAP-displaying or control phage particles, and were per-
fused with PBS after 24 h, followed by collection of tumors and
control organs. For phage detection and quantification, half of each
tissue sample was snap-frozen in liquid nitrogen and the other half
was fixed in PBS containing 10% (vol/vol) buffered formalin
(pH 7.4) and paraffin-embedded. Frozen tissues were homogenized
with a glass Dounce homogenizer, suspended in 1 mL DMEM
supplemented with 1 mM PMSF, 20 μg/mL aprotinin, 1 μg/mL
leupeptin, and washed three times in the same medium. Phage
particles were detected by IHC of FFPE sections as described
previously (33). Phage DNA was isolated with the DNeasy Blood
and Tissue Kit (Qiagen) from frozen tissues, and amounts were
determined by qPCR on a 7500 Fast Real-Time PCR System
(Applied Biosystems) as described previously (34).
GRP78-Targeting AAVP-Based Theranostics: Molecular-Genetic
Imaging and Targeted Therapy. Experimental protocols for the
generation of AAVP-based vectors have been described in tech-
nical detail elsewhere (22; reviewed in refs. 23–25). Vectors were
purified from MC1061 Escherichia coli, resuspended in PBS and
centrifuged to remove residual debris. GRP78-targeting AAVP-
containing supernatants were titrated by K91 E. coli infection.
Mice implanted with the MDA-PCa-118b PDX received a single-
dose intravenously (1 × 1011 TU per mouse) of SNTRVAP-dis-
playing or control AAVP particles 7 d after tumor implantation.
Treatment with GCV at 80 mg/kg daily intraperitoneally was ini-
tiated 5 d after vector administration and continued daily for 7 d.
PET/CT imaging was performed 24 h after the last GCV dose to
allow sufficient time for residual clearance of GCV by metabolism
or elimination. Tumor metabolic activity was determined by ad-
ministration of radiolabeled [18F]-FDG followed by PET and CT
scans. On the following day, HSVtk expression was determined in
PET and CT scans acquired 2 h after intravenous administration
of the radiolabeled substrate [18F]-FEAU. PET scans were ob-
tained with a microPET R4 (Concorde Microsystems), equipped
with a computer-controlled positioning bed in a 10.8-cm transaxial
and 8-cm axial field-of-view with no septa and operating in 3D list
mode. PET/CT imaging was performed with an Inveon micro-
PET/CT scanner (Siemens Preclinical Solution). PET and CT
image fusion and analysis were performed with ASIPro 5.2.4.0
(Siemens Preclinical Solution). To quantify [18F]-FEAU, regions
of interest were drawn on digitized images, and measured values
were converted from nanocurie per cubed millimeter (nCi/mm3)
to the percentage of injected dose per gram of tissue (% ID/g), as
described previously (26, 39).
Supplemental Discussion: Comparison Between the [18F]-FEAU and
124I-FIAU Substrates. The 124I-FIAU substrate used in the com-
panion article (46) can produce low nonspecific signals because of
its affinity for endogenous TK1 (nuclear) and TK2 (mitochondrial)
enzymes. In contrast, the 18F-FEAU used in this study has no
enzymatic substrate affinity for TK1, as demonstrated by several
previous studies by Gelovani’s group (39, 53–55). Although FEAU
has considerable affinity for TK2, the mitochondrial localization of
this enzyme and very tight control of the thymidine pools inside
mitochondria result in almost no uptake of FEAU, even in highly
proliferative tumors (39, 53–55). In addition to these observa-
tions, 18F-FEAU is expected to provide cleaner background levels
of radioactivity in nontarget tissues and less whole body and indi-
vidual organ radiation dose exposures than 124I-FIAU, because 124I
has a larger fraction of high-energy spectrum emissions and lon-
ger decay half-life (∼4 d) compared with 18F (∼2 h). We used the
two different substrates in the two studies to compare their tumor
selectivity. In both cases, we reached similar and specific im-
aging signals, with just a slight difference in the background
observed. However, given the associated reasoning above, we
will use 18F-FEAU in future translational studies.
Statistics.Data were analyzed by two-way ANOVA corrected with
Bonferroni’s test (for multiple comparisons of in vivo experi-
ments), or by Student’s t test (for paired comparisons of in vitro
experiments). Data are presented as the mean ± SEM, unless
otherwise specified. P values of less than 0.05 were considered
statistically significant. All statistical analyses were performed
with the Prism software v5.01 (GraphPad Software).
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